ReviewJournal of atherosclerosis and thrombosis2018
Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis.
Review in Journal of atherosclerosis and thrombosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 60 citations in OpenAlex.
- Tumor-driven arginine depletion induces T-cell metabolism reprogramming to suppress atherosclerosis in colorectal cancer.Acta pharmacologica Sinica · 2026Article
- Late-Onset Hypertension Is Associated With Improved Clinical Outcomes in Cancer Patients Treated With Sunitinib.Circulation reports · 2026Article
- Chemo-/radiotherapy-induced cardiomyopathy: roles of mitochondria and endoplasmic reticulum.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- Impact of cancer treatments on coronary plaque as assessed by integrated backscatter intravascular ultrasound.Cardiology journal · 2026Article
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Predicting Cardiovascular Risk Factors for Acute Leukemia Patients by Assessing Subclinical Atherosclerosis and Left Ventricular Function Before Chemotherapy.Life (Basel, Switzerland) · 2025Article
- Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha.International journal of molecular sciences · 2025Article
- Anticancer Chemotherapy-Induced Atherosclerotic Cardiovascular Disease: A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Overview and Future Direction of Embolic Stroke of Undetermined Source from the Insights of CHALLENGE ESUS/CS Registry.Journal of atherosclerosis and thrombosis · 2024Review
- Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicity.Cardio-oncology (London, England) · 2024Article
- Molecular Linkage between Immune System Disorders and Atherosclerosis.Current issues in molecular biology · 2023Review
- Prevalence and trends of perioperative major adverse cardiovascular and cerebrovascular events during cancer surgeries.Scientific reports · 2023Article
- Article
- TSPAN4 is a prognostic and immune target in Glioblastoma multiforme.Frontiers in molecular biosciences · 2022Article
- Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis:JACC. CardioOncology · 2021Review
- Distinction in Prevalence of Atherosclerotic Embolic Sources in Cryptogenic Stroke With Cancer Status.Journal of the American Heart Association · 2021Article
- Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments.Current treatment options in oncology · 2021Review
- Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.Cancer chemotherapy and pharmacology · 2021Observational
- Tumor Necrosis Factor Alpha-Mediated Inflammation and Remodeling of the Extracellular Matrix Underlies Aortic Stiffening Induced by the Common Chemotherapeutic Agent Doxorubicin.Hypertension (Dallas, Tex. : 1979) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of new chemotherapeutic and immunotherapeutic treatments has markedly improved outcomes in patients with cancer. However, increasing numbers of elderly patients with cancer and prolonged periods of treatment have made the management of cardiovascular complications and treatment-induced cardiotoxicity an important concern, and onco-cardiology has received increasing attention. The number of patients with cardiotoxicity, particularly atherosclerotic lesions, and the usage of angiogenesis inhibitors have increased, making the involvement of onco-cardiologists essential for effective disease management. A paradigm shift in immunotherapy was caused by the development of immune checkpoint inhibitors. Because vascular endothelial growth factors (VEGF) in the cancer microenvironment and cancer immune function are interrelated angiogenesis inhibitors will most likely play an increasingly important role in combined immunotherapy. To ensure the optimal long-term diagnosis and long-term treatment of cancer and the effective management of treatment-related atherosclerotic diseases, the long-term continuous participation of onco-cardiologists is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.